{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 37,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "go_to_market",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a hub-and-spoke style layout to categorize strategic pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/22",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.26,
        "y": 0.85
      },
      "kind": "callout",
      "text": "~350M annual revenue (est.)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2510158e-2136-459c-9c17-8c485679d023",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.12
      },
      "kind": "callout",
      "text": "Drivers of Market Penetration",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6566eaf3-e3bc-445e-8c5f-776f8d675317",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.3,
        "y": 0.33
      },
      "kind": "list",
      "text": "Self-Manufacturing: Large-Scale cGMP Manufacturing. Control of Production Schedule. Attractive COGs. Ability to scale up modular process.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62076bd5-e721-4109-bcc0-59a0164ea842",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "list",
      "text": "Partnerships: Leverage partnership with GOG Foundation. Preeminent US-based cooperative group in Gynecologic Oncology. Composed of leading KOLs in the field. Partners in the OnPrime/GOG-3076 Phase 3 registration trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "703cf932-fe50-40e7-a7e2-a6a159ecfb81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.53,
        "y": 0.33
      },
      "kind": "list",
      "text": "Patients: Underappreciated Population. ~236,511 Ovarian Cancer Patients in the US. 70-80% will relapse with few therapeutic options. Limited number of Gyn-Oncs enabling specialty sales team.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb56dee4-591f-44cc-9135-e6ce7b4afac3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.76,
        "y": 0.33
      },
      "kind": "list",
      "text": "Reimbursement: Compelling Value Proposition for Payors. Significant unmet medical need. Combination with generic/biosimilars. Future label expansion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0e4d2a2-fbf8-4d1d-a84d-8aa47ff4f428",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.16,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. NIH Ovarian Cancer Fact Sheet",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31c74d0d-b8a4-49d0-8562-0e6212dc1167",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Self Launch Olvi-Vec for Ovarian Cancer in the US",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44d3fa75-6d42-45e0-997c-ff30a4b32ded",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "409d413e-98bc-498a-a7b4-7818b3148619",
      "evidence": "Patients: Underappreciated Population. ~236,511 Ovarian Cancer Patients in the US. 70-80% will relapse with few therapeutic options.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}